Figure 4: | Scientific Reports

Figure 4:

From: Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2

Figure 4:

ACE2-RBD inhibitory response and binding activity of serological IgG against RBD variants. The ACE2-RBD binding inhibitory response for seven RBD variants at (A) pre-vaccination, (B) post–dose 1, (C) peak response post-dose 2, and (D) 6 months post-dose 1 were evaluated by ELISA. (E) Response at four timepoint were represented as a heatmap. Data analyzed by Kruskal–Wallis test followed by Dunn’s test. Data represented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.01, ****p < 0.0001. Serological IgG binding activity to seven RBD variants (F–I) at four timepoints were measured by ELISA. Results were analyzed by Kruskal–Wallis test followed by Dunn’s test. N = 168, *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page